Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Receivables (2022 - 2026)

Axsome Therapeutics' Receivables history spans 5 years, with the latest figure at $251.1 million for Q1 2026.

  • On a quarterly basis, Receivables rose 42.5% to $251.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $251.1 million, a 42.5% increase, with the full-year FY2025 number at $224.5 million, up 44.35% from a year prior.
  • Receivables hit $251.1 million in Q1 2026 for Axsome Therapeutics, up from $224.5 million in the prior quarter.
  • Over the last five years, Receivables for AXSM hit a ceiling of $251.1 million in Q1 2026 and a floor of $16.2 million in Q2 2022.
  • Historically, Receivables has averaged $125.6 million across 5 years, with a median of $124.3 million in 2024.
  • Biggest five-year swings in Receivables: surged 413.75% in 2023 and later skyrocketed 41.99% in 2025.
  • Tracing AXSM's Receivables over 5 years: stood at $37.7 million in 2022, then soared by 184.68% to $107.3 million in 2023, then soared by 44.9% to $155.5 million in 2024, then skyrocketed by 44.35% to $224.5 million in 2025, then rose by 11.85% to $251.1 million in 2026.
  • Business Quant data shows Receivables for AXSM at $251.1 million in Q1 2026, $224.5 million in Q4 2025, and $196.5 million in Q3 2025.